Olema Pharmaceuticals (NASDAQ:OLMA) Releases Quarterly Earnings Results

Olema Pharmaceuticals (NASDAQ:OLMA) released its quarterly earnings data on Tuesday. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.12, Zacks reports.

Olema Pharmaceuticals Trading Down 7.0 %

Shares of NASDAQ OLMA opened at $4.14 on Wednesday. The company has a market cap of $237.21 million, a price-to-earnings ratio of -1.89 and a beta of 2.11. Olema Pharmaceuticals has a 12 month low of $3.95 and a 12 month high of $16.62. The stock has a 50-day moving average price of $5.18 and a two-hundred day moving average price of $8.46.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a research report on Tuesday, March 11th.

Insider Activity

In other news, major shareholder Bain Capital Life Sciences Inv acquired 300,000 shares of the stock in a transaction dated Wednesday, January 8th. The stock was bought at an average price of $5.76 per share, with a total value of $1,728,000.00. Following the completion of the purchase, the insider now directly owns 7,800,000 shares of the company’s stock, valued at $44,928,000. This represents a 4.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 19.40% of the stock is currently owned by insiders.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.